XML 248 R191.htm IDEA: XBRL DOCUMENT v3.25.0.1
Off balance sheet commitments - Summary of Off Balance Sheet Commitments Relating to Operating Activities (Details)
€ in Millions, $ in Billions
 12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Disclosure Of Off Balance Sheet Commitments [Line Items]        
Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced     € 554 [1] € 221
Irrevocable purchase commitments given [2]     3,683  
Irrevocable purchase commitments received     (391)  
Research and development license agreements - commitments related to R&D and other commitments     84 [3] 381
Research and development license agreements - contingent milestone payments in connection with development programs in progress     4,230 [4] 4,886
Total - net commitments given     8,160  
Lease, term 12 years 15 years    
Lease, cost | $ $ 0.2 $ 0.2    
Lease, extension options, number   2    
Lease, extension options, term   5 years    
Minimum        
Disclosure Of Off Balance Sheet Commitments [Line Items]        
Lease, term   12 years    
EUROAPI        
Disclosure Of Off Balance Sheet Commitments [Line Items]        
Irrevocable purchase commitments given     535  
Less than 1 year        
Disclosure Of Off Balance Sheet Commitments [Line Items]        
Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced [1]     28  
Irrevocable purchase commitments given [2]     1,152  
Irrevocable purchase commitments received     (288)  
Research and development license agreements - commitments related to R&D and other commitments [3]     42  
Research and development license agreements - contingent milestone payments in connection with development programs in progress [4]     941  
Total - net commitments given     1,875  
From 1 to 3 years        
Disclosure Of Off Balance Sheet Commitments [Line Items]        
Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced [1]     34  
Irrevocable purchase commitments given [2]     1,195  
Irrevocable purchase commitments received     (96)  
Research and development license agreements - commitments related to R&D and other commitments [3]     29  
Research and development license agreements - contingent milestone payments in connection with development programs in progress [4]     635  
Total - net commitments given     1,797  
From 3 to 5 years        
Disclosure Of Off Balance Sheet Commitments [Line Items]        
Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced [1]     41  
Irrevocable purchase commitments given [2]     442  
Irrevocable purchase commitments received     (7)  
Research and development license agreements - commitments related to R&D and other commitments [3]     6  
Research and development license agreements - contingent milestone payments in connection with development programs in progress [4]     470  
Total - net commitments given     952  
More than 5 years        
Disclosure Of Off Balance Sheet Commitments [Line Items]        
Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced [1]     451  
Irrevocable purchase commitments given [2]     894  
Irrevocable purchase commitments received     0  
Research and development license agreements - commitments related to R&D and other commitments [3]     7  
Research and development license agreements - contingent milestone payments in connection with development programs in progress [4]     2,184  
Total - net commitments given     3,536  
Suppliers        
Disclosure Of Off Balance Sheet Commitments [Line Items]        
Irrevocable purchase commitments given       6,141
Irrevocable purchase commitments received       (550)
Suppliers | Opella Business        
Disclosure Of Off Balance Sheet Commitments [Line Items]        
Irrevocable purchase commitments given       € 754
Joint ventures        
Disclosure Of Off Balance Sheet Commitments [Line Items]        
Irrevocable purchase commitments given     € 749  
[1] (a)Includes the variable portion of future lease payments not recognized as lease liabilities as of December 31, 2024; the equivalent amount of these
commitments as of December 31, 2023 was €221 million.
During 2023, Sanofi signed a 15-year lease which will take effect in 2025 and to which Sanofi is committed for a minimum period of 12 years,
corresponding to a commitment of $0.2 billion. The lease includes two extension options of five years each.
During 2024, Sanofi signed a 12-year lease in France which will take effect in 2027, representing a commitment of €0.2 billion.
[2] (c)Irrevocable purchase commitments given as of December 31, 2024 include €749 million of commitments to joint ventures. This line also includes (i) the
commitment to EUROAPI as described in Note D.1. and amounting to €535 million as of December 31, 2024, and (ii) commitments related to long-term
renewable energy purchase contracts lasting between 15 and 20 years giving rise to the physical supply of electricity mainly in France for an estimated
total annual volume of 329 GWh.
[3] (d)Commitments related to research and development, and other commitments, amounted to €381 million as of December 31, 2023.
[4] (e)This line only includes contingent milestone payments on development projects in progress. The equivalent amount as of December 31, 2023 was  €4,886 million